Regina Vincenzi Oliveira

Associate Professor III of the Department of Chemistry at the Federal University of São Carlos, with emphasis on High Performance Liquid Chromatography and Mass Spectrometry (LC-MS), mainly in the following topics: bioanalytical methods, direct injections of biological samples, use of Dried Matrix Spot (DMS), drug metabolism, targeted and untargeted metabolomics, investigation and quantification of endogenous biomarkers, bioanalysis of monoclonal antibodies, proteins and biotherapeutic peptides, and treatment of biological samples using immunocapture techniques. Dr. Oliveira was a postdoctoral fellow at the National Institute of Health, National Institute on Aging in Baltimore, MD (2004-2006), where she received an award for excellence in scientific research. She served as a Visiting Researcher at Quintiles, Inc. in Ithaca, NY (USA) (2012-2013), in a scientific project in collaboration with Eli Lilly Pharmaceutical Company (Indianapolis, IN), acting in the bioanalysis of drugs in dried blood spot samples and high resolution mass spectrometry ( DBS-HRMS). From April/2015 to June/2017, she served as Senior Research Investigator at Bristol-Myers Squibb in Princeton NJ working on the discovery and analysis of endogenous biomarkers and biotherapeutic molecules (monoclonal antibodies, proteins and peptides) for clinical and preclinical support in TRD in the following therapeutic areas: Cardiovascular, Oncology, Immuno-oncology and Fibrosis. She currently works as a Senior Research Investigator at Massachusetts General Health, a Teaching Hospital of Harvard Medical School, being responsible for the metabolomics platform by LC-HRMS and GC-MS, where the projects focus on understanding the role of genes in cancer control, interpretation of how cells modulate their growth and use energy in response to nutrients. Additional studies explore how some therapies targeting key mutations cause tumor growth to stop and why they eventually develop resistance. (Source: Lattes Curriculum)